Trials / Completed
CompletedNCT06698016
A Study of the Effect of Efavirenz on the Plasma Levels of Nemtabrutinib (MK-1026-014)
A Study to Evaluate the Effect of Multiple Oral Doses of Efavirenz on the Single-Dose Pharmacokinetics of Nemtabrutinib in Healthy Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 16 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
The goal of the study is to learn what happens to levels of nemtabrutinib (MK-1026) in a healthy person's body over time. Researchers will compare what happens to nemtabrutinib in the body when it is given with or without another medicine called efavirenz.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nemtabrutinib | Oral administration |
| DRUG | Efavirenz | Oral administration |
Timeline
- Start date
- 2023-07-25
- Primary completion
- 2023-10-30
- Completion
- 2023-10-30
- First posted
- 2024-11-20
- Last updated
- 2024-11-20
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06698016. Inclusion in this directory is not an endorsement.